Ariad readies for launch of first cancer treatment
The company is focusing on sales — along with science — as its promising first therapy awaits approval
Ariad Pharmaceuticals Inc. has spent two decades in classic biotechnology start-up mode. Company scientists have labored at designing drugs and identifying diseases to target, while its investors have waited for Ariad’s first product to hit the market. Some time soon, the perseverance may finally pay off. Federal regulators have granted priority review to the biotech’s experimental treatment for chronic myeloid leukemia, promising to decide by March 27 whether the company, founded in 1991, can start selling the drug in the United States.